Global Stem Cell And Applications Market Set To Grow To $25.1bn By 2023

02 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Stem Cell Technologies and Applications Market 2018-2018: Cancer, Cardiovascular, CNS, Other Disease Areas and Non-Therapeutic Applications

Visiongain believes that the next ten years in the stem cell market will see many crucial breakthroughs, including: multiple approvals, particularly in the cardiovascular segment but increasingly also in the CNS segment; increased use and clinical validation of hESCs and iPSCs; and major changes in the drug development process, enabled by new stem cell-based assays.

The lead analyst of the report commented “Advances in related areas of regenerative medicine, such as tissue engineering, bioprinting and biomaterials, could interact with stem cell development to generate new opportunities to treat disease. Organ regeneration would be a high priority for companies in this area; tissue engineering of a thymus using stem cells is an example. 3D printing could be used to form scaffolds and tissues for orthopaedic conditions and wound healing.

New technologies will be needed to ensure that scaling-up of manufacturing operations can be done effectively once stem cell treatments enter the market. Scalability is often cited as one of the major barriers in translating promising pre-clinical and clinical-stage results into a valid and commercially viable therapy.”

Leading companies featured in the report include Mesoblast, Pharmicell, NuVasive, Orthofix, MEDIPOST, Reliance Life Sciences, Gamida Cell, Neuralstrem, ReNeuron, Apceth, Novartis, TiGenix, Ocata Therapeutics, Athersys.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever